|Videos|June 28, 2023
Choosing Between BCMA and Non-BCMA Bispecifics in Multiple Myeloma Treatment
Experts explain the strategies for optimal selection between different BCMA-targeting and non-BCMA-targeting bispecifics for the treatment of relapsed/refractory multiple myeloma.
Advertisement
Episodes in this series
Advertisement
Related to this article
Saad Z. Usmani, MD, MBA, FACP, FASCO, discussed the threshold he will act on in standard-risk disease, and the trial that would make the decision firmer.
In a retrospective analysis, teclistamab produced response rates numerically higher than in MajesTEC-1, with missed doses not compromising outcomes.
Data from the phase 3 OCEAN trial and others support the expanded approval for melflufen in patients with previously treated multiple myeloma.
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Advertisement
Advertisement
Trending on CancerNetwork
1
Real-World Teclistamab Shows Deep Responses in R/R Multiple Myeloma Cohort
2
Adding Pembrolizumab to SBRT Does Not Improve EFS in Early-Stage NSCLC
3
ArteraAI Prostate Test Added to NCCN Guidelines for BCR After Prostatectomy
4
Virtuoso Robotic System Earns FDA De Novo Nod for En Bloc Bladder Resection
5